Contact
Please use this form to send email to PR contact of this press release:
Bispecific Antibody Drug Conjugates Outlook 2024-2029 Featuring Alphamab, Amgen, AstraZeneca, Beijing Biocytogen, BiVictriX, Corellia AI, Debiopharm, Doma Bio, Genmab, Innovent, ProEn Therapeutics - ResearchAndMarkets.com
TO: